Thrombo-prevention in membranous nephropathy: a new tool for decision making?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24875548.
- Also identified by DOI 10.1038/ki.2013.541.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thromboembolic events occur in primary membranous nephropathy, especially when serum albumin is less than 2.8 g/dl. In such patients, a conundrum arises concerning anticipated benefits and risks when a prophylactic oral anticoagulant is considered. Lee et al. describe a flexible Markov decision tree program to aid decision making. Its application to individual patients will probably be useful, but physicians will need to assess patients' tolerance for the benefit-to-risk ratio, considering the many factors bearing on the risk of thromboembolic events and/or serious bleeding.
Medical subject headings
- Anticoagulants
- Decision Support Techniques
- Glomerulonephritis, Membranous
- Patient Selection
- Venous Thromboembolism